Bruce Imbert

Bruce Imbert

Auto-generated profile, based on publicly available information

Bruce Imbert

Pear Therapeutics, Inc Boston, MA United States

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 August 2013 in Alcohol, Clinical and Experimental Research
Verified
Journal Article
Closed access
PDF file
AMAmélie Marsot
Amélie Marsot
BIBruce Imbert
Bruce Imbert
JAJean Claude Alvarez
Jean Claude Alvarez
SGStanislas Grassin-Delyle
Stanislas Grassin-Delyle
IJIsabelle Jaquet
Isabelle Jaquet
Nicolas SimonNicolas Simon
Nicolas Simon

24 July 2015 in Alcohol, Clinical and Experimental Research
Verified
Journal Article
Closed access
PDF file
BIBruce Imbert
Bruce Imbert
JAJean Claude Alvarez
Jean Claude Alvarez
Nicolas SimonNicolas Simon
Nicolas Simon

1 October 2013 in Journal of Clinical Psychopharmacology
Verified
Journal Article
Closed access
BIBruce Imbert
Bruce Imbert
JCJulien Cohen
Julien Cohen
Nicolas SimonNicolas Simon
Nicolas Simon

15 November 2013 in Therapeutic Advances in Psychopharmacology
Verified
Journal Article
Closed access
BIBruce Imbert
Bruce Imbert
NLNathalie Labrune
Nathalie Labrune
CLChristophe Lancon
Christophe Lancon
Nicolas SimonNicolas Simon
Nicolas Simon
Cannabis is the most commonly used illicit drug in the world. However, only few studies have shown the efficacy of pharmacologic agents in targeting cannabis withdrawal symptoms or reducing the reinforcing effects of cannabis. Baclofen has been shown to reduce cannabis withdrawal symptoms and the subjective effects of cannabis. We think that the clinical utility of baclofen for cannabis dependence is a reasonable approach. A case report using baclofen is presented and provides preliminary support for the use of baclofen in the management of cannabis dependence.

25 April 2013 in Alcohol and Alcoholism
Verified
Journal Article
Open access
PDF file
HCHelene Clarisse
Helene Clarisse
BIBruce Imbert
Bruce Imbert
RBRaoul Belzeaux
Raoul Belzeaux
IJIsabelle Jaquet
Isabelle Jaquet
CLChristophe Lancon
Christophe Lancon
Nicolas SimonNicolas Simon
Nicolas Simon

26 January 2022 in JMIR Research Protocols
Verified
Journal Article
Open access
HLHilary Luderer
Hilary Luderer
LCLisa Chiodo
Lisa Chiodo
AWAmanda Wilson
Amanda Wilson
CBChristina Brezing
Christina Brezing
SMSuky Martinez
Suky Martinez
ACAimee Campbell
Aimee Campbell
Background: Prescription digital therapeutics are software-based disease treatments that are regulated by the US Food and Drug Administration; the reSET-O prescription digital therapeutic was authorized in 2018 and delivers behavioral treatment for individuals receiving buprenorphine for opioid use disorder. Although reSET-O improves outcomes for individuals with opioid use disorder, most of the therapeutic content is delivered as narrative text. PEAR-008 is an investigational device based on reSET-O that uses an interactive, game-based platform to deliver similar therapeutic content designed to enhance patient engagement, which may further improve treatment outcomes. Objective: We aim to investigate how participants interact with the prescription digital therapeutic’s new content delivery format. Secondary objectives include evaluating treatment success, symptoms of co-occurring mental health disorders, recovery capital, and skill development. Methods: Due to the COVID-19 pandemic, this study was redesigned using a decentralized model because it was not possible to conduct medication initiation and study visits in person, as initially intended. A decentralized, randomized controlled trial design will be utilized to compare patient engagement with PEAR-008 and that with reSET-O using both subjective and objective assessments. The study population will consist of approximately 130 individuals with opioid use disorder (based on Diagnostic and Statistical Manual of Mental Disorders 5 criteria) who have recently started buprenorphine treatment for opioid use disorder. Participants will be virtually recruited and randomly assigned to receive either PEAR-008 or reSET-O. All study sessions will be virtual, and the duration of the study is 12 weeks. The primary outcome measure of engagement is operationalized as the number of active sessions per week with either PEAR-008 or reSET-O. (An active session is any session that contains some active participation in the app, such as navigating to a different screen, engaging with a learning module, or responding to a notification.) Subjective dimensions of engagement will be assessed with participant surveys. The hypothesis is that PEAR-008 will have significantly greater participant engagement than reSET-O. Results: As of February 2021, participant enrollment is ongoing. Conclusions: This randomized controlled trial will investigate if changing the delivery format and enhancing the content of a prescription digital therapeutic for opioid use disorder will affect how participants use and interact with the prescription digital therapeutic. The study design may serve as a useful model for conducting decentralized studies in this patient population. Trial Registration: ClinicalTrials.gov NCT04542642; https://clinicaltrials.gov/ct2/show/NCT04542642 International Registered Report Identifier (IRRID): DERR1-10.2196/32759